Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of 20vPnC in Adults ≥65 with Prior Pneumococcal Vaccination
NCT03835975Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2019
- Primary completion
- Feb 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 3 trial of Prevnar 20 in pneumococcal disease, sponsored by Pfizer. Started Feb 2019; status: completed.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT03835975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03835975.